Immunome (IMNM) Share-based Compensation (2019 - 2026)

Immunome's Share-based Compensation history runs 8 years deep, the most recent figure standing at $8.0 million for Q1 2026.

• Quarterly Share-based Compensation rose 39.45% year-over-year to $8.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $27.9 million (up 44.83% YoY) and the FY2025 annual result came in at $81.5 million, up 8.38% from the prior year.
• Share-based Compensation was $8.0 million for Q1 2026 at Immunome, up from $7.9 million in the prior quarter.
• Across five years, Share-based Compensation topped out at $8.0 million in Q1 2026 and bottomed at $1.0 million in Q2 2023.
• A 5-year average of $3.5 million and a median of $2.2 million in 2024 frame the typical range for Share-based Compensation.
• Annual changes were most pronounced in 2023 — Share-based Compensation retreated 22.16% — and 2024, when it soared 395.47%.
• Immunome's Share-based Compensation stood at $1.4 million in 2022, then decreased by 18.52% to $1.1 million in 2023, then surged by 395.47% to $5.5 million in 2024, then surged by 44.3% to $7.9 million in 2025, then advanced by 0.76% to $8.0 million in 2026.
• Business Quant data shows IMNM's Share-based Compensation at $8.0 million in Q1 2026, $7.9 million in Q4 2025, and $6.7 million in Q3 2025.